Xtant Medical Holdings (NYSE:XTNT) announced on April 13, 2026, that it has secured exclusive U.S. distribution rights for HEMOBLAST Bellows, a specialized hemostatic powder developed by Dilon Technologies.
The agreement marks a significant portfolio expansion for Xtant as it seeks to capture a larger share of the global surgical hemostats market, currently estimated at $2 billion.
HEMOBLAST Bellows is a pre-loaded, ready-to-use hemostatic agent designed to manage minimal to moderate bleeding during surgical procedures.
The product's proprietary formula—a combination of collagen, human thrombin, and bovine chondroitin sulfate—requires no prior preparation or mixing, offering surgeons a streamlined solution for rapid clot formation in the operating room.
As part of the strategic agreement, Xtant will integrate Dilon’s existing U.S. commercial infrastructure, including an approximately 20-person specialized sales team.
This addition is expected to immediately bolster Xtant's sales force, providing deeper penetration into hospital systems and ambulatory surgery centers where the company already maintains a presence with its orthobiologic and spinal implant lines.
The acquisition of distribution rights allows Xtant to enter the high-margin surgical adjunct market without the traditional R&D overhead associated with new product development.
The "plug-and-play" nature of the HEMOBLAST Bellows applicator is specifically designed for ease of use in diverse surgical specialties, including orthopedic, spinal, and general surgery.
Financially, Xtant expects the deal to be a key driver for the remainder of the year.
The company stated it will provide a formal update to its full-year 2026 financial guidance when it reports its first-quarter 2026 results.